Glycosa
  • Home
  • Introduction
  • Status of the MVP
  • Strategic Partnerships
  • Current Stages
  • Human Trials and Promise
  • Team
  • Investor Relations
  • More
    • Home
    • Introduction
    • Status of the MVP
    • Strategic Partnerships
    • Current Stages
    • Human Trials and Promise
    • Team
    • Investor Relations
Glycosa
  • Home
  • Introduction
  • Status of the MVP
  • Strategic Partnerships
  • Current Stages
  • Human Trials and Promise
  • Team
  • Investor Relations
Product Evolution - MVP Development Cycle

We have been able to place five versions of our device in a very reliable and up-to-date laboratory for two years, and during this time we have performed more than 7000 clinical tests on patients.

In recent version, we reduced the number of fingers to 2 by changing the sensor shape and type for improved accuracy.

Our Clinical trials

RELIABLE ACCURACY

We have been able to place five versions of our device in a very reliable and up-to-date laboratory for two years, and during this time we have performed more than 7000 clinical tests on patients. The average accuracy of the last version of our device is about 88% (or 11.5% - MAPE).

PERSONALIZATION:

The personalization feature is one of the advantages of our device, as personalization can reduce errors and increase accuracy.

Expanded clinical trials
  • Home
  • Introduction
  • Status of the MVP
  • Strategic Partnerships
  • Current Stages
  • Human Trials and Promise
  • Team
  • Investor Relations

Copyright © 2024 GLYCOSA - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept